Please join us for a plenary-style meeting and reception with representatives from Novo Nordisk and Novo Holdings’ Venture Investments team.
*This session is separate from the earlier 1:1 partnering meetings and is open to a broader audience.
During the program, Novo Nordisk and Novo Holdings Venture Investments will outline their areas of interest for innovation partnering through an interactive panel discussion, followed by a complimentary networking reception.
Representatives from Novo Nordisk and Novo Holdings Venture Investments will be in attendance and are particularly interested in connecting with local academic institutions, research organizations, venture capital firms, and companies with programs and technologies complementary to their pipeline and capabilities. They welcome opportunities that enhance or support their efforts to address unmet medical needs in serious disease areas.
Agenda:
4:30 p.m. to 5:00 p.m. | Registration and Networking
5:00 p.m. to 6:00 p.m. | Plenary Session
6:00 p.m. to 7:00 p.m. | Closing Networking Reception
Please note:
- We reserve the right to cancel the participation of direct competitors.
- This session is closed to non-member service provider companies (those not currently members of Biocom California).
About Novo Nordisk:
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries.
We partner with leading scientists, academic and medical institutions, technology startups, biotech innovators and pharmaceutical companies, to turn bold ideas into groundbreaking solutions that are available to patients across the globe. We believe that partnerships come down to creating more value together than we each could alone – by combining innovative ideas with the experience of bringing them to life.
Learn more about partnering with Novo Nordisk
About Novo Holdings Venture Investments:
Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation, one of the world’s largest enterprise foundations.
Novo Holdings is the controlling shareholder of Novo Nordisk and Novonesis (the Novo Group companies) and manages an investment portfolio with a long-term return perspective. Novo Holdings invests in life science companies at all stages of development and, in addition, manages a broad portfolio of equities, bonds, real estate and infrastructure assets as well as private equity investments. As of year-end 2024, Novo Holdings had Total Assets under Management of DKK 1,060bn (€142bn).
The Novo Holdings Venture Investments team is one of the largest and most active international life science venture investors, with a 25-year track record of investing in novel therapies. The Venture Investments portfolio includes both privately held and publicly traded investments in the biotech, medtech and digital health sectors, and spans early-stage, translatable science through commercial stage products. Novo Holdings’ evergreen structure enables the Venture Investments team to take a long-term view to advance science and medicine for the benefit of society. Venture Investments operates globally, with teams based in San Francisco, Boston, London and Copenhagen, with additional support from Novo Holdings’ Asia Investment teams in Singapore and Shanghai.
